Application of nanotechnology in cancer research: Review of progress in the National Cancer Institute's alliance for nanotechnology

International Journal of Biological Sciences

Volumn 3, Issue 2, 2007, Pages 108-110

  Ehdaie, Beeta ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; COPOLYMER; DOCETAXEL; GELATIN; IRON OXIDE; MACROGOL; NANOPARTICLE; PACLITAXEL; POLY(ETHYLENE OXIDE) CO POLY(BETA AMINO ESTER) COPOLYMER; QUANTUM DOT; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURGERY; DRUG DELIVERY SYSTEM; LETTER; NANOTECHNOLOGY; NONHUMAN; OVARY ADENOCARCINOMA; PROSTATE CANCER; TUMOR VOLUME;

EID: 33846910312     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.3.108     Document Type: Letter

References (16)

1. Amiji M, Park K. Prevention of protein adsorption and platelet adhesion on surfaces by PEO/PPO/PEO triblock copolymers. Biomaterials. 1992; 13: 682-692.
2. Amiji M, Park K. Surface modification of polymeric biomaterials with poly(ethylene oxide): a steric repulsion approach. In: Shalaby SW, Ikada Y, Langer R, Williams J (ed) Polymers of biological and biomedical significance. American Chemical Society symposium series publication. 1994; 540:135-146.
3. Devalapally H, Shenoy D, Little S, Langer R, Amiji M. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3 Therapeutic efficacy and safety studies in ovarian cancer xenograft model. Cancer Chemotherapy and Pharmacology; in press.
4. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature. 1990; 346: 818-822.
5. Farokhzad OC, Karp JM, Langer R. Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin. Drug Deliv. 2006; 3: 311-324.
6. Farokhzad OC, Cheng J, Teply BA, et al. Nanoparticle-aptamer bioconjugates result in significant tumor reduction in vivo. Proc. Natl Acad Sci USA. 2006; 103 (6): 6315-6320.
7. Ferrari M. Cancer Nanotechnology: Opportunities and Challenges. Nature Rev. Cancer. 2005; 5:161-171.
8. Ferrari M, Barker AD, Downing GJ. A Cancer Nanotechnology Strategy. NanoBiotechnology. 2005; 1:129-131.
9. Grodzinski P, Silver M, Molnar LK. Nanotechnology for Cancer Diagnostics: Promises and Challenges. Expert Rev. Mol. Diagn. 2006; 6 (3):307-318.
10. Hanahan D, Weingberg RA. The Hallmarks of Cancer. Cell.2000; 100: 57-70.
11. Jemal A, et al. Cancer Statistics 2006. CA Cancer J Clin. 2006; 56(2): 106-130.
12. Kommareddy S, Amiji M. Biodistribution and Pharmacokinetic Analysis of Long-Circulation Thiolated Gelatin Nanoparticles Following Systemic Administration in Breast Cancer-Bearing Mice. J Pharm Sci; in press.
13. McNeil, SE. Nanotechnology for the Biologist. Journal of Leukocyte Biology. 2005; 78: 585-594.
14. Moghimi SM, Muir IS, Illum L, Davis SS, Kolb-Bachofen V. Coating particles with a block co-polymer (polox-amine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. Biochem Biophys Acta.1993; 1179: 157-165.
15. Sathe TR, Agrawal A, Nie S. Mesoporous Silica Beads Embedded with Semiconductor Quantum Dots and Iron Oxide Nanocrystals: Dual-Function Microcarriers for Optical Encoding and Magnetic Separation. Anal. Chemistry. 2006; 78: 5627-5632.
16. Tan JS, Butterfield DE, Voycheck CL, Caldwell KD, Li JT. Surface modification of nanoparticles by PEO/PPO block copolymers to minimize interactions with blood components and prolong blood circulation in rats. Biomaterials.1993; 14: 823-833.